Google Custom Search
Podcast Advocacy 2014 HBV Meeting navigation menu


PA Biotech
Liver Cancer Connect
Visit our Baruch Blumberg Institute of Living Science
World Hepatitis Alliance Member
HepB United

Top Stories    

*Please Note: Links to full articles may expire after 2 weeks. If you are unable to access the page via the links below, try searching the HBV Research List Archives at


Potential Cure for Hepatitis B Enters Phase 1/2a Clinical Trial
Dec 15 – A new treatment developed by Walter and Eliza Hall Institute researchers to promote the cure of chronic hepatitis B virus infection is now recruiting patients for a phase I/2a clinical trial. Read more.

Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
Dec 15 – Antiviral treatment patterns for chronic hepatitis B among pregnant and nonpregnant women provides a baseline for assessing changes in treatment patterns in this open source article written by CDC authors. Increased use of antivirals to prevent breakthrough perinatal hepatitis B infection is anticipated. Read more.

Prize-winning Hepatitis B Mobile App Diagnostic Tool
Dec 15 – Students and faculty from Stanford University have developed a portable device that can be used to run diagnostic tests including the detection of the hepatitis B infection, which can be completed within 10 minutes. Read more.

Mold on Corn Can Cause Liver Cancer
Dec 15 – Certain molds that may grow on corn, pistachios, and peanuts, produce a deadly carcinogenic toxin that is a risk factor for liver cancer. Professor Felicia Wu and her team at Michigan State are working to identify cost-effective, feasible aflatoxin prevention methods in developing countries. Read more.

Preventing, Treating HBV Reactivation During Immunosuppressive Therapy
Dec 8 - Patients who are to undergo immunosuppressive therapy but are at high risk for reactivation of hepatitis B infection should receive antiviral prophylaxis, rather than being monitored for reactivation and treated only if it develops, according to a new guideline published online in Gastroenterology. Read more.

Tumor Microenvironment of Hepatitis B Virus-Associated Hepatocellular Carcinoma
Dec 8 – Scientists review critical issues of tumor microenvironment in hepatocellular carcinoma (HCC) summarizing the components and mechanisms to demonstrate underlying themes and the inherent complexity of these interacting systems in the initiation and progression of HBV associated HCC. Read more.

Pakistani Blood Transfusions Spreading Hepatitis, HIV
Dec 8 – Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with viral hepatitis. Read more.

Delhi Govt Launches Online Hepatitis Immunisation Campaign
Dec 8 – An online campaign to spread awareness about hepatitis immunization was launched by the Delhi government's health department in collaboration with the Institute of Liver and Biliary Sciences (ILBS) as part of the Hepatitis Awareness Week. Read more.

Many IBD Patients Don't Get Hepatitis B Vaccine
Dec 1 – Most patients with inflammatory bowel disease (IBD) do not receive screening for or vaccination against the hepatitis B virus, according to a new study looking at a large tertiary gastroenterology practice. Read more.

Hepatitis B Vaccine Produced Cheaply and Efficiently Using GMO Corn
Dec 1 – A small technology venture, called Applied Biotechnology Institute (ABI) has developed a method to genetically modify corn to produce an affordable, easy-to-administer vaccine for hepatitis B. Read more.

A Project for a Vaccine Against Hepatitis C and B Rewarded by the French National Academy of Medicine
Dec 1 – The Hepatibivax project funded by ANR has been awarded the Drieu-Cholet prize from the National Academy of Medicine for its progress in the development of a vaccine targeting the viruses of both hepatitis B and C. Read more.

Tenofovir Continues to Work Well Against Hepatitis B Virus for 8 Years
Nov 27 - Most chronic hepatitis B patients treated with tenofovir (Viread) for 8 years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2014. Read more.

Study Implicates Triclosan in Development of Liver Fibrosis and Cancer in Mice
Nov 27 – Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items, but despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially serious consequences of long-term exposure to the chemical. Read more.

Survivor of 4 Brothers Determined to Fight Liver Cancer
Nov 27 – Baltazar Lucas lost all of his siblings to liver cancer caused by hepatitis B in a five-year period, from 2008 to 2013. Today, he is in danger of losing his own life, having been diagnosed late last year with the same dreaded disease, which decimated his family. Read more.

AGA's Journals Highlight Important Updates Into Treatments for Cirrhosis, NAFLD
Nov 27 – Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. A new promising probiotic for liver disease and additional NAFLD treatment information are highlighted in December AGA journals. Read more.

Hepatitis B Flares are Common During Cancer Chemotherapy: Presented at AASLD
Nov 17 – The abrupt elevation of serum alanine aminotransferase (ALT) over 5 times the upper limit of normal indicates flare-up of hepatitis B virus infection, and is a common occurrence during cancer chemotherapy, according to results from a retrospective study presented at the Liver Meeting 2014. Read more.

Hundreds of Former Patients Tested for HIV or Hepatitis After 'Unhygienic' Dentist is Accused of Ignoring Infection Control Rules
Nov 17 – More than 22,000 patients of an “unhygienic” dentist are thought to be at possible risk for hepatitis B, hepatitis C and HIV, and have been urged to come forward for testing in what is believed to be the biggest recall in UK medical history. Read more.

Drug Combo Disappoints in Hepatitis B
Nov 10 – Treatment with a combination of tenofovir and pegylated interferon cured only a small fraction of patients with chronic hepatitis B, though the combination treatment was better than either drug alone, or a shorter combination of the two, as reported at the annual AASLD Liver Meeting. Read more.

New Study Focuses On Improving Care for Hepatitis-B-Infected Asian Americans
Nov 10 – Nearly 60 percent of infected Asian Americans fail to seek regular monitoring and treatment of hepatitis B. Grace Ma, professor and director of the Center for Asian Health in Temple University’s College of Public Health plans to conduct a study aimed at improving adherence to regular monitoring and treatment of the disease among infected Asian Americans. Read more.

Are US Veterans Being Appropriately Tested and Treated for Hepatitis B?
Nov 10 – The rates of serologic testing for HBV conducted by the VA were suboptimal as recommended by the AASLD practice guideline, according to an examination of the VA’s Corporate Data Warehouse. The study revealed that HBV infection is twice as common in the Veteran population as in the general population of the country. Read more.

Hepatitis B Relapse is Common After Stopping Antiviral Therapy
Nov 10 – Hepatitis B virus rebounded in nearly 80% of people treated with fully or partially suppressive antiviral therapy using adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir), or tenofovir (Viread), indicating that long-term therapy is usually needed to control the virus, researchers reported. Read more.

Fighting Viral Hepatitis in the African Region
Nov 10 – Countries in the African Region should establish strong and well-resourced surveillance systems in order to detect viral hepatitis, a growing public health threat in Africa, suggests Dr. Luis Sambo, Regional Director for Africa, World Health Organization. Read more.

Barriers Remain in Educating People With Diabetes of Their Increased Hepatitis B Risk
Nov 10 - Diabetes educators cite a lack of time and competing priorities during counseling sessions with patients as key barriers to educating their adult patients with diabetes about vaccination against hepatitis B, according to a new survey by the American Association of Diabetes Educators (AADE) and GSK. Read more.

Daily Checkup: The Link Between Hepatitis B and Liver Cancer
Nov 3 – About 1 in 30 people worldwide has chronic hepatitis B, the main underlying cause of liver cancer. Dr. Steven Brower, a liver cancer specialist at Mount Sinai Beth Israel, speaks out in honor of Liver Cancer Awareness Month. Read more.

HBV Prevalent in Ugandan Pregnant Mothers and Increased Early Childhood Transmission
Nov 3 – Hepatitis B is highly prevalent in Uganda, with a national average of 10%, but with a much higher prevalence of 20% in Northern Uganda. In this Ugandan study, researchers looked at pregnant women and transmission to their babies.  Read more.

Scientists Pursue Novel Blood Tests for Cancer
Nov 3The inventor of a breakthrough DNA test for Down syndrome says the
technology can also be used to screen people for cancer, and is testing his technique following people infected with hepatitis B at risk for liver cancer. Read more.

Vaccinations 'Not Linked to Increased Risk of MS, Central Nervous System Disorders'
Oct 27 – Previous research has suggested that certain vaccinations may increase the risk of central nervous system disorders, including multiple sclerosis. But a new study published in JAMA Neurology finds no such association. Read more.

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B
Oct 27 - Results from proof-of-concept clinical trials suggest Myrcludex B, a novel entry inhibitor, indicate positive results for the treatment of chronic HBV and may become an option for treating hepatitis delta. Read more.
Hepatitis B Virus Replication, E Antigen Secretion Reduced With Entecavir
Oct 27 – A combination of Entecavir plus turin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion making this a promising therapy for those with chronic HBV. Read more.

Judge Upholds Citations Issued for Bloodborne Pathogen and Lead Exposure
Oct 27 – Unfirst Corp. has been cited for violations of its Bloodborne Pathogens Standard, including failure to conduct proper training and provide Hepatitis B vaccinations to drivers and loading-dock workers exposing them to hazards. Read more.

9 Facts About Your Liver
Oct 20 – October is Liver Awareness and Liver Cancer Awareness Month! You might not think twice about your liver, but here’s why you should. Read more.

Tekmira Pharma Presents TKM-HBV Preclinical Study Data
Oct 20 – Tekmira Pharmaceuticals presented preclinical results showing potent and rapid reduction of hepatitis B surface antigen (HBsAg) demonstrated using TKM-HBV, their therapeutic agent targeting hepatitis B. Read more.

Liver Transplanted Second time in Hong Kong Man
Oct 20 - Hong Kong surgeons have performed a double world first with a transplant from one Hepatitis B sufferer to another with a liver that had already been transplanted once 11 years ago. Read more.

Obesity May Speed Aging of the Liver, Study Suggests
Oct 20 – Extra pounds cause the liver to age faster, potentially explaining why obesity is linked to diseases like liver cancer and insulin resistance, new research suggests. Read more.

Multimedia Information Drive for Hepatitis B Launched
Oct 13 - The World Health Organization, in tandem with the Hepatology Society of the Philippines, launched the B-Aware Campaign, an awareness campaign to spread information about hepatitis B and to alleviate discrimination in the Philippines.  Read more.

Liver Awareness Month: A Good Time to Clean Up Our Act
Oct 13 – October is Liver Awareness Month! What a great time to focus on the fabulous things that your liver does for your body and your health. Read more.

Drinking Decaf or Regular Coffee Maybe Good for the Liver, Study Suggests
Oct 13 – Higher coffee consumption, regardless of caffeine content, was linked to lower levels of abnormal liver enzymes, according the NCI researchers and published in Hepatology. This suggests that chemical compounds in coffee other than caffeine may help protect the liver. Read more.

Chicken, Fish Lower Liver Cancer Risk
 Oct 13 – The health benefits of upping your intake of poultry and fish are many and varied, but a new study has shown such consumption can significantly lower the risk of liver cancer. Read more.

People With Hepatitis B Who Have Cirrhosis Should Be Prioritized for Liver Cancer Screening
Oct 6 – Liver cancer screening for people with HBV infection should be targeted at those with cirrhosis. The risk of hepatocellular carcinoma (HCC) and death were 31- and 44- times higher, respectively, in people with liver cirrhosis compared to people who did not have cirrhosis. Read more.

The Hepatitis Scare (Philippines)
Oct 6 – One-out-of-eight Filipinos (equivalent to 16 million people) or 16% of the country is currently suffering from hepatitis B, especially among 20-39 year olds. HBV is also a root of discrimination, work restriction, and subsequent disqualification from employment. Read more.

“Gold of Pleasure” Oilseed Boosts Liver Detoxification Enzymes
 Oct. 6 - University of Illinois scientists have found compounds that boost liver detoxification enzymes nearly fivefold, and they've found them in a pretty unlikely place - the crushed seeds left after oil extraction from an oilseed crop used in jet fuel. Read more.

Lack of Political Will by Gov’t Hampering Fight Against Hepatitis
Sept 29 – The President of the Hepatitis B Foundation, Mr. Theobald Owusu-Ansah, has hinted that government is not doing enough in dealing with hepatitis B in Ghana. Read more.

Hope For People With Liver Failure — Artificial Livers Now Become a Reality
Sept 29 – A bio-artificial liver support system for patients suffering from acute liver failure is on its way, as investigations are done to assess its safety and effectiveness, according to new research. Read more.

Genetic Driver of Inflammation Uncovered, Used to Prevent and Treat Liver Cancer
Sept 29 – Blocking the expression of a gene known as astrocyte elevated gene-1 (AEG-1) halts the development and progression of liver cancer by regulating inflammation, demonstrated for the first time by scientists at Virginia Commonwealth University Massey Cancer Center. Read more.

Expert Calls For Enlightenment On Hepatitis B in Nigeria
Sept 22 - A gastroenterologist, Dr Olutoyin Asaolu, has called for enlightenment and collaboration among stakeholders in order to reduce the burden of Hepatitis B in the country of Nigeria. Read more.

Australian Govt Called to Act on Hepatitis Death Rate
Sept 22 – Hepatitis Australia, which represents the half a million Australians with viral hepatitis, has called for immediate government intervention to prevent a "tidal wave" of life-threatening liver disease. Read more.

Spreading Fast: Lack of Treatment Drug Leaves Patients Helpless Against Hepatitis
Sept 22 - Patients in Khyber-Pakhtunkhwa, Pakistan are suffering due to a shortage of quality interferon, a medicine used to treat viral hepatitis. Read more.

Involvement of the Host DNA-Repair Enzyme TDP2 in Formation of the Covalently Closed Circular DNA Persistence Reservoir of Hepatitis B Viruses
Sept 22 – Scientists from the recent 2014 international Meeting, Molecular Biology of Hepatitis B Viruses, published a new paper in PNAS, the official journal of the U.S. National Academy of Sciences!  Read more.

OnCore Biopharma Licenses 2nd Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
Sept 15 – Located in the PA Biotech Center in Doylestown, OnCore secures exclusive rights to NVP018, which will complement their existing pipeline directed at achieving an all-oral cure for hepatitis B. Read more.

Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients
Sept 15 - Although it is widely understood that hepatitis B and hepatitis C are the leading causes of liver cirrhosis and liver cancer, a study published in Cancer Nursing reports an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health. Read more.

Increase Seen in Liver Injury Caused by Herbals, Dietary Supplements
Sept 15 – New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period. Read more.

SAARC Experts Join Hands to Combat Liver Diseases
Sept 15 – With rising incidences of liver diseases in South Asian countries, experts from SAARC nations have come together to chalk out strategies to combat these diseases in the region and will include effective guidelines for the prevention and treatment. Read more.

Novira Completes Phase 1a Clinical Study of NVR-1221 for Treatment of HBV Infection
Sept 8 – Novira Therapeutics, a privately held biopharmaceutical company in the PA Biotech Center, developing novel therapies for curative treatment of chronic hepatitis B, announced successful completion of a Phase 1a clinical study that demonstrated NVR-1221 was safe and well-tolerated at all doses. Read more.

What You Need to Know About Hepatitis B
Sept 8 – A few days after World Hepatitis Day, Mandaluyong became the first city in the Philippines to initiate the B Positive movement, an advocacy initiative aimed at raising proactive awareness towards Hepatitis B. Read more.

A Potential Breakthrough On Liver Cancer
Sept 8 – An exciting breakthrough has occurred that might just reduce the burden of liver cancer through prevention, and possibly in a timelier manner. Read more.

Fight Brewing Over Liver Donation
Sept 8 – United Network for Organ Sharing (UNOS), the nonprofit that manages the nation's transplant system, will hold a public hearing to discuss ways to "increase equity" in how organs are assigned to patients across the country, particularly donated livers. Read more.

Could Your Dentist’s Office Give You HIV or Hepatitis B?
Sept 2 – Concerned about the increasing number of cases where patients undergoing dental treatments are detected with HIV and Hepatitis, medical experts caution that patients must ensure that the doctor open the examination instruments from a sterilized pouch in their presence. Read more.

Defectors’ Overall Health Lags Behind, Study Shows
Sept 2 – North Korean defectors are more susceptible to certain diseases, including hepatitis B, compared to their South Korean counterparts, according to a study by the Korea Centers for Disease Control and Prevention. Read more.

Carcinogenic Role of a Protein in Liver Decoded
Sept 2 – The human protein EGFR, which controls cell growth has served as a point of attack for target-oriented therapies, but a new discovery may lead to more effective treatment strategies to fight hepatocellular carcinoma.  Read more.

Campaign Focuses on Reducing HBV in Chinese City
Aug 25 – The Hepatitis B Foundation (HBF) joined forces with the Haimen City Center for Disease Control and Prevention for a 3-year campaign to educate clinicians, civic leaders and the city’s general population of 1 million residents on hepatitis B. Read the interview with HBF’s Chari Cohen in Healio Hepatology, and the BMC Public Health publication.

Immunization Program Protects Babies From Hepatitis B
Aug 25 – The transmission of hepatitis B from mother to child has been virtually eliminated in Kaiser Permanente’s Northern California region, thanks to a program, which ensures that babies receive all recommended shots on time. Read more.

Dentist Surrenders License Over HIV, Hepatitis Scare
Aug 25 – An Oklahoma oral surgeon whose filthy clinics led to the testing of thousands of patients for HIV and viral hepatitis permanently surrendered his professional license. Read more.

Doctors ID New Ways to Get More Kids Vaccinated
Aug 25 – Doctors are still struggling to find effective ways to convince wary parents of the importance of vaccinating their infant children, and have a new way to identify and approach parents that are hesitant to vaccinate infants. Read more.

Viral Hepatitis More Deadly than HIV, but Unfunded
Aug 18 – In what has become a cruel public health irony, not being HIV positive is a lethal disadvantage experienced by millions of people with chronic hepatitis and no access to life-saving drugs. Read more.

HKU Researchers’ New Liver Cancer System Helps Prolong Patients’ Lives
Aug 18 – Hong Kong researchers have developed Asia’s first system that classifies liver cancer patients into different stages to receive more targeted treatment, doubling patients’ median survival time and improving survival rates of those in more advanced stages. Read more.

Two Friends, a Big Heart and a Shared Liver
Aug 18 – A touching story involving two longtime friends and former roommates, and the gift of lifesaving living-donor transplantation. Read more.

Gateway to Care Campaign: A Public Health Initiative to Reduce the Burden of Hepatitis B in Haimen City, China
Aug 11 – Check out HBF’s first peer–reviewed publication from our 3-year Haimen City project, including a public health campaign targeting city residents, health care professionals, community leaders, and pregnant women. Haimen City has one of the highest incidences of liver cancer and mortality in China and the world. This city–wide education and awareness campaign reached almost 300,000 residents. Read more.

Model of Viral Lifecycle Could Help in Finding a Cure for Hepatitis B
Aug 11 – A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease. Read more.

Lack of Action Against Viral Hepatitis Causes Asia Pacific to Suffer
Aug 11 – In the Asia Pacific region, viral hepatitis kills over one million people every year, with a death rate three times higher than HIV/AIDS and nine times higher than malaria. Viral hepatitis causes 78% of all liver cancer globally, and liver cancer is the second most common cause of cancer death worldwide, yet only half of the countries surveyed in Asia Pacific have a national action plan to prevent and control the spread of viral hepatitis. Read more.

NICE Renews Efforts To Prevent Hepatitis
Aug 11 – The National Institute for Health and Care Excellence (NICE) announced new quality standards aimed at the preventing hepatitis B transmission and improving the lives of those living with the condition in the UK. Read more.

Gilead Allows India & China To Produce Generic HIV/HBV Drug
Aug 4 – Gilead Sciences announced it has reached a new agreement with the Medicines Patent Pool to expand access to their investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval. Read more.

Hepatitis is Still the Silent Killer
Aug 4 – After rounding out a week of World Hepatitis Day events, Congressional Champions bring attention to the viral hepatitis epidemic and encourage other Congressional members to prioritize hepatitis. Read more.

‘Yellow Warriors’ Fight Not Just Virus but also Stigma of Hepa B
Aug 4 – Yellow is the color of courage for some people whose daily lives have been shaped by the physical and emotional challenges of battling Hepatitis B. The Yellow Warriors Society Philippines (YWSP) is a national organization of hepatitis B and C sufferers who have become advocates, particularly in the fight against HBV related discrimination. Read more.

Mouth Bacteria Invade the Gut in Liver Cirrhosis Patients
Aug 4 – Gut microbiota of individuals with liver cirrhosis differ notably from healthy individuals showing a high proportion of oral bacteria, and permitting the discovery of a non-invasive test for liver cirrhosis, accurate to over 90%. Read more.

Stephen Colbert Report Gives World Hepatitis Day Shout-Out Stephen Colbert Report Gives World Hepatitis Day Shout-Out
July 28 – Comedian Stephen Colbert on his daily show features World Hepatitis Day!




U.S. White House Live Webcast for World Hepatitis Day
July 28 – Tune in Wednesday, July 30 from 12:00-3:00pm EST, for a Live Webcast from the White House observance of World Hepatitis Day and to recognize hepatitis leaders that includes the Hepatitis B Foundation’s Executive Director! Tune in here.

WHO Welcomes Global Momentum On Viral Hepatitis
July 28 – Today on World Hepatitis Day, the World Health Organization welcomes new progress in tackling one of the world’s most serious diseases. Read more.

Viral Hepatitis Now Kills More People Than HIV/AIDS
July 28 – A major new analysis published in The Lancet highlights positive progress on the global burden of HIV/AIDS. Viral hepatitis, however, remains neglected and faces significant challenges to address the spiraling mortality rate. Read more.

Biochemist's Find is New Hope for Hep B Cure
July 21 – Dr. Adam Zlotnick at Indiana University has discovered a class of antiviral small molecules that target the viral DNA hidden in the infected livers of hepatitis B patients and could lead to a cure. Novel compounds based on these discoveries, known as Core Protein Allosteric Modulators, or CpAMs, are capable of altering the activities of a core hepatitis B protein that is essential for the virus’s continued survival. Read more.

New York City's Top Hospitals Fail to Vaccinate Newborns Against Hep B, Study Shows
July 21 – All babies should receive the hepatitis B vaccination as soon as they’re born, federal officials say, but advocates say some of the city’s top hospitals are not following recommendations, putting the babies at risk for infection. Two of the hospitals with the lowest vaccination rates in the city are Mount Sinai and Beth Israel, where fewer than 20 percent of babies received the HBV vaccine in 2012, according to Health Department data. And at Maimonides, Tisch and Roosevelt hospitals, just 20 to 40% of newborns got the vaccine that same year. Read more.

HBV Rebounds After Stopping Entecavir, Switching to Interferon May Help
July 21 – Most hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B patients relapsed after stopping treatment with the antiviral drug entecavir (Baraclude), according to a report Gut. A related study found that switching from entecavir to pegylated interferon increased the likelihood of HBeAg seroconversion and hepatitis B surface antigen (HBsAg) loss in HBeAg positive patients. Read more.

Screening for Hepatitis B Virus Infection: A Public Health Imperative
July 7 – Annals of Internal Medicine editorial provides a clear rationale for the updated USPSTF recommendations, and reflects the HBF’s position on screening for hepatitis B. Read more.

Tenofovir Usually Suppresses Hepatitis B in HIV/HBV Coinfected People
July 7 – Tenofovir led to undetectable hepatitis B virus levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in Hepatology. Read more.

Super-Cooled Livers Could Bring New Flexibility to Organ Transplants
July 7 – In liver transplantation, one of the biggest inequities is geographic. A group of Harvard University researchers has come up with a preservation technique that could one day allow livers to be shared more easily around the world. Read more .

Drug Everolimus Fails to Improve Overall Survival in Advanced Liver Cancer Patients
July 7 – Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Read more.

No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment
June 30 – No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in Clinical Gastroenterology and Hepatology. Read more.

GAVI Alliance Addresses MSF Concerns on Infant Hepatitis B Vaccine
June 30 – Medecins Sans Frontieres recently expressed concern about the slow implementation of the World Health Organization’s recommendation that a dose of hepatitis B vaccine be delivered immediately after birth, and the GAVI alliance has resplied. Read more.

Fighting Hepatitis B and Liver Cancer in West Africa
June 30 – EU-funded researchers are identifying and treating patients with Hepatitis B in West Africa with the aim of reducing their risk of dying from liver cancer. The researchers are also developing a new test to identify those with liver cancer, so treatment can be given sooner – saving more lives. Read more.

Okyeame Kwame Fights Against Hepatitis B
June 30 – As part of activities to mark this year’s World Hepatitis B Day, Ghana’s award-winning hiplife artiste, Okyeame Kwame, will organize a free Hepatitis B screening event for 5000 people in Accra. Read more.

Screening Can Identify Early-Stage HCC But Benefits Unclear
June 23 – Chronic hepatic disease has been recognized as a risk factor for hepatocellular carcinoma, but does that mean that all patients should be screened? See what a recent study published in the Annals of Internal Medicine has to say. Read more.

WHO Calls for National Actions on Hepatitis
June 23 – Though home to about one quarter of the world population, the WHO Region for the Western Pacific accounts for nearly 50% of the 160 million chronic hepatitis B infections worldwide. Read more.

HIV infection Due to Unsafe Medical Injections May Have Fallen by Almost 90% Worldwide in Decade After 2000
June 23 – The number of HIV, hepatitis B and C infections in low and middle-income acquired due to unsafe medical injections fell by 87%, 83%, and 91% respectively between 2000 and 2010. "This is a remarkable public health achievement.” Read more.

Mayo Clinic Study Reverses Current Thought on Treatment of Cirrhosis
June 23 – Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. Read more.

Something to Celebrate: Improved Guidelines for Hepatitis B Screening
June 2 – The month of May gave us many reasons to celebrate. Reflecting on Asian American and Pacific Islander (AAPI) Heritage and Hepatitis Awareness Month, appreciating the rich AAPI history, and recognizing the importance of addressing viral hepatitis in AAPI populations. Read more.

Combating the Silent Epidemic of Hepatitis B in the AAPI Community
June 2 – Dr. Howard Koh, Assistant Secretary of Health, HHS, reminds us of the staggering impact of Hepatitis B in Asian American and Pacific Islanders, and how coordination and collaboration among federal partners works to reduce the burden of hepatitis B in these communities. Read more.

Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
June 2 – Among HBV/HCV coinfected people, about half have dominant hepatitis B virus while half have dominant hepatitis C, and those with active HBV replication are at higher risk of liver-related complications and death, according to study findings presented at Digestive Disease Week. Read more.

Hepatitis Warrior Hiking in China Shows Glaxo Hurdles
June 2 – Lei Chuang trekked almost 1,000 miles over 80 days from Shanghai to Beijing last summer, along riverbanks and highways, to deliver a petition beseeching China’s leaders to cut the prices of hepatitis B drugs. Read more.

Screening for Hepatitis B Virus Infection: A Public Health Imperative
May 26 – The U.S. Preventive Services Task Force, a national panel of health experts, advised that doctors should regularly screen people at high risk for contracting the hepatitis B virus. Read more.

World Health Assembly Approves Resolution on Viral Hepatitis and Noncommunicable Dieases
May 26 – The World Health Assembly has approved a resolution to improve the prevention, diagnosis, and treatment of viral hepatitis, as well as proposals to improve global coordination of efforts to address noncommunicable diseases. Read more.

Passing Hepatitis B From Mother to Child Halted With Vaccine
May 26 – The passing of the hepatitis B virus, a primary cause of liver cancer, from mother to child can be virtually eliminated by immunizing high-risk newborns within hours of birth and following up with vaccinations over the baby's first six months of life, according to a large, recently published, Northern California Kaiser study. Read more.

Talking About Hepatitis B and HIV: Working to End the Stigma
May 26 – Hepatitis B and HIV have stigmatizing effects within the Asian American and Pacific Islander communities. Read Mei’s personal account of how she copes. It’s time to diffuse the stigma. Read more.

Alnylam's Hepatitis B Therapy Shows Promise in Animal Studies
May 19 – RNAi specialist Alnylam is adding a hepatitis B therapy to its pipeline of candidates that employ its enhanced stabilization chemistry-GalNAc-conjugate technology enabling subcutaneous dosing. Read more.

Robust Hepatitis B Seroprotection in Adolescence After Immunization in Infancy
May 19 – The complete hepatitis B vaccine series given in childhood has been shown to provide protection against HBV into adulthood. However the duration of protection if administered in infancy was uncertain, raising the question, is a booster dose of the vaccine in adolescence necessary? Read more.

What Every Women Needs to Know about Hepatitis B and C
May 19 – In observance of National Women’s Health Week and Hepatitis Awareness Month, Health and Human Services (HHS) Viral Hepatitis Policy Advisor Corinna Dan, takes the opportunity to raise viral hepatitis awareness among women. Read more.

Treating Hepatitis B and C in HIV + People Reduces Liver Disease
May 19 – Effective antiviral treatment that suppresses hepatitis B virus replication or eradicates hepatitis C virus can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL. Read more.

Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
May 12 – Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at Digestive Disease Week. Read more.

HBV: Community-Based Programs May Improve Care
May 12 – Community outreach programs, helped along by funding from the Centers for Disease Control and Prevention, may be improving the screening, treatment, and care of patients with hepatitis B virus infection, according to an article published in the Morbidity and Mortality Weekly Report. Read more.

Novira Kicks Off Phase 1a Trial of Novel Hep B Drug
May 12 – Novira Therapeutics Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus infection, announced that it initiated a Phase 1a clinical study of NVR-1221. The Phase 1a clinical study is designed to assess the pharmacokinetic profile and dose-related safety and tolerability of NVR-1221 in healthy volunteers. Read more.

Screening May Help Boost Liver Cancer Survival Rates
May 12 – Increased screening for liver tumors in people with cirrhosis could help boost liver cancer survival rates, according to researchers, but unfortunately they found less than 20% of at-risk people are being tested. Read more.

May is Hepatitis Awareness Month
May 5 – Throughout May, during this year’s observance of Hepatitis Awareness Month, federal colleagues from across the U.S. Departments of Health and Human Services, Housing and Urban Development, Justice, and Veterans Affairs will be engaged in a variety of activities to increase awareness—among the public and healthcare providers—about viral hepatitis. Read more.

The B Positive Program as a model to reduce hepatitis B health disparities in high-risk communities in Australia
May 5 – The B Positive Program addresses the challenges in diagnosing and managing hepatitis B in culturally and linguistically diverse communities in high-risk communities in Australia. Read more.

Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission
May 5 – An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the 2014 EASL International Liver Congress. Read more.

Acetaminophen in Rx drugs: For Liver's Sake, Lower the Dose, Says FDA
May 5 – A Food and Drug Administration (FDA) warning was missed by many physicians, pharmacists and patients, so the FDA, in an unusual move, reminds us: Stop writing prescriptions for, stop dispensing prescriptions for, and stop taking prescription medications containing more than 325 milligrams of acetaminophen. Read more.

Some Immigrants In Columbus At Risk For Silent Killer
April 28 – Central Ohio is home to some 70,000 Asian immigrants, and advocates worry the silent deadly disease, hepatitis B, is hidden in the population. Read more.

Hepatitis B is Not Hindrance For Work
April 28 – Employers should neither isolate nor discriminate against workers who are Hepatitis B positive, the Hepatology Society of the Philippines (HSP) strongly voiced. HSP has written the Guidelines on the Evaluation of Hepatitis B Surface Antigen Positive Workers for Employment to dispel misconceptions and lack of knowledge about HBV in the Philippines. Read more.

Herbal Medicines and Supplements Carry Risk of Hepatoxicity
April 28 – Herbal medicines and other home remedies or supplements are a significant cause of hepatotoxicity experts warned recently during a symposium at the International Liver Congress. Read more and watch the videos.

Fiji Babies Covered
April 28 – This year’s immunization week celebrations in Fiji are focused on promoting vaccination against hepatitis B with the theme ‘Stop hepatitis B and liver cancer – Vaccinate at Birth’. Read more.

Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
April 21 – Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49th EASL International Liver Congress last week in London. Read more.

Asia-Pacific Nations Prodded On Hepatitis Action Plans
April 21 – Health experts state that the Asia-Pacific region needs more cross-sector partnerships and funding to tackle viral hepatitis, and they are calling on countries in the Asia-Pacific to set national action plans to address the escalating impact of viral hepatitis. Read more.

Teen Makes Genetic Discovery of Her Own Rare Cancer
April 21 – Inspiring story of a teen with a rare from of liver cancer that not only recovered from her cancer, but embarked on a scientific journey using YouTube to reach out to other patients to collect tumor samples that would eventually lead to a cutting edge discovery. Read more and watch the videos.

Can Coffee Treat Liver Disease?
April 21 – Contemporary studies suggest that coffee is beneficial for chronic liver diseases and can positively impact liver function tests, viral hepatitis, and may even help prevent cirrhosis and liver cancer. Read more.

Three New Studies Help Clarify Optimal Use of Combination Therapy in Chronic Hepatitis B Patients
April 14 - Three new studies presented at the International Liver Congress 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues to achieve the best treatment outcomes in patients with chronic hepatitis B. Read more.

Viral Hepatitis More Deadly Than HIV in Europe
April 14 – Mortality from viral hepatitis is significantly higher than from HIV/AIDS across European Union (EU) countries, according to results from The Global Burden of Disease Study 2010, which was announced for the first time at the International Liver Congress 2014. Read more.

Small Cash Incentives Dramatically Improve Hepatitis B Vaccination Rates Among Injecting Drug Users
April 14 – Modest financial incentives significantly improve adherence to hepatitis B virus vaccination programs among patients receiving opioid dependence treatment, according to a study published in The Lancet. Read more.

New Marker to Predict Recurrence of Hepatocellular Carcinoma
April 14 – High preoperative levels of hepatitis B surface antigen (HBsAg) in patients with a low viral load predict an increased likelihood of hepatocellular carcinoma recurrence after resection, Chinese researchers report. Read more.

Updated Viral Hepatitis Action Plan Released
April 7 – An updated version of the nation’s first comprehensive cross-governmental action plan to combat chronic viral hepatitis, initially launched in 2011, has been released. The Action Plan for the Prevention, Care and Treatment of Viral hepatitis builds upon the progress accomplished over the past three years. Read more.

Screening for Liver Cancer in Patients With Cirrhosis
April 7 – Patients with cirrhosis who underwent surveillance via liver ultrasound for hepatocellular carcinoma had cancers detected at an earlier stage, and were more likely to receive curative instead of palliative treatment, and had longer survival. Read more.

High Hepatitis B Antigen Predicts Hepatic Cancer Recurrence
April 7 – The risk of hepatocellular carcinoma recurrence increased with high levels of hepatitis B surface antigen (HBsAg) , specifically at HBsAg above 1000 IU/mL. Read more.

Some of Us are Turning Our Livers Into 'Foie Gras'
April 7 – While most of us are more familiar with viral hepatitis, alcohol-related liver disease and liver cancer, there is another condition affecting the liver that is insidiously rising amongst the world population. Read more.

Hep B Cure Could Be Discovered in Bucks Co.
March 24 – When a hepatitis B cure is discovered, it might very well happen inside the walls of the Pennsylvania Biotechnology Center in Bucks County. Read more.

Entecavir Approved for Children 2 Years and Older for Hepatitis B virus Infection
March 24 – The U.S. Food and Drug Administration has approved the antiviral entecavir (brand name Baraclude) for use in children and teens age 2 and older. This robust antiviral is the first to be approved by the FDA for children in several years, and is considered one of the top two antivirals available to adults today. Read more.

Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients
March 24 – Arrowhead Research Corporation announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter. Read more.

Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B Virus
March 24 – Isis Pharmaceuticals announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49th annual meeting of the European Association for the Study of the Liver (EASL). Read more.

Responding to the Escalating Impact of Viral Hepatitis in Asia Pacific
March 17 – Professor Ding-Shinn Chen, Chair of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), addresses newly released data which CEVHAP will use to continue to raise awareness of the escalating impact of viral hepatitis in the Asia Pacific region. Read more.

HCC Risk Remains High With Hep B Antivirals
March 17 – Chronic hepatitis B patients who achieve complete response with oral antiviral therapy are still at much higher risk of developing hepatocellular cancer compared to patients with inactive chronic hepatitis B, Korean researchers find. Read more.

Vertical Transmission of Hep B On the Way Out
March 17 – Tenofovir in pregnant women with hepatitis B is extremely effective in preventing in utero infection and in combination with vaccination could eradicate the disease altogether, a New Zealand expert says. Read more.

Roadside Barbers: Main Cause of Communicable Diseases
March 17 – The use of unsterilized equipment by roadside barbers is the main cause of spreading communicable diseases, including Hepatitis B and C, in the twin cities of Pakistan. Read more.

Hepatera Completes Enrollment of Phase IIa Clinical Trial of Myrcludex B, for HBV
March 10 – A group of 48 patients infected with the hepatitis B virus have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd., with the aim to study safety, tolerability and efficacy. Read more.

Metabolic Profiling of Liver Cells Suggests New Treatments for Cirrhosis Patients
March 10 – In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University–led team of researchers examined the metabolic breakdown that takes place in liver cells during late–stage cirrhosis and found clues that suggest new treatments to delay liver failure. Read more.

Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
March 10 – Biostar Pharmaceuticals, Inc., a China–based manufacturer and marketer of pharmaceutical and health supplement products, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Read more.

Hepatera Completes Enrollment of Phase IIa Clinical Trial of Myrcludex B, for HBV
March 10 – A group of 48 patients infected with the hepatitis B virus have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd., with the aim to study safety, tolerability and efficacy. Read more.

Metabolic Profiling of Liver Cells Suggests New Treatments for Cirrhosis Patients
March 10 – In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University–led team of researchers examined the metabolic breakdown that takes place in liver cells during late–stage cirrhosis and found clues that suggest new treatments to delay liver failure. Read more.

Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
March 10 – Biostar Pharmaceuticals, Inc., a China–based manufacturer and marketer of pharmaceutical and health supplement products, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Read more.

Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
March 3 – Arrowhead Research Corporation announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus infection. Read more.

Adult Immunization Retake: Lost Opportunities for Protection, Shared Responsibility
March 3 – According to Medscape, only 65% of healthcare professionals have been vaccinated to protect against hepatitis B in the U.S. Read more.

WHO Official Urges Hepatitis B Education in China
March 3 – While praising China’s efforts in reducing hepatitis B, Dr. Shin Young-soo, the World Health Organization (WHO) Western Pacific regional director, stressed more effort is needed to fight discrimination against hepatitis B virus carriers in China. Read more.

Small man, Great Power
March 3 – A chronic hepatitis B carrier in China shows the impact one, small man can have by empowering others with his sense of justice, and his courage to disclose his chronic HBV infection, and publicly raise awareness. Read more.

Degradation of Viral DNA in the Cell Nucleus Opens New Hepatitis B Treatment Possibilities
Feb 24 – New data reveals how the viral DNA of the hepatitis B virus can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated, without damage to the liver cell, report scientists from the Helmholtz Zentrum München and the Technische Universität München in the journal, Science. Read more.

Hepatitis B Virus-Related Hepatocellular Carcinoma is Induced by MicroRNA-181a
Feb 24 – Researchers at Chongqing Medical University in China broke new ground on an association between microRNAs and hepatocellular carcinoma, the second leading cause of cancer-related deaths worldwide. Read more.

How to Turn Skin Cells Into Functioning, Mature Liver Cells
Feb 24 – Researchers have discovered a way to transform skin cells into mature, fully functioning liver cells that flourish on their own, even after being transplanted into laboratory animals modified to mimic liver failure, raising the hopes for millions at risk for developing liver failure. Read more.

WHO: Liver Cancer Moves to the 2nd Leading Cause of Cancer Deaths in the World
Feb 17 – Based on the latest statistics from WHO on trends in cancer incidence and mortality worldwide, the cancer burden is growing, and liver cancer has moved from third to now the second leading cause of cancer death worldwide. Read more.

Are Doctors Screening Their Patients for Hepatitis B?
Feb 17 – Dr. Curtis T. Miyamoto, president of the Philadelphia County Medical Society, speaks with HBF’s own Chari Cohen and Daniel Chen about local efforts and encourages hepatitis B screening of at-risk patients. Read more.

Austrian Red Cross in Hot Water After ‘Rejecting’ Blood Donations From Muslims
Feb 17 – Austria's Red Cross has come under fire from the local Islamic community after one of its doctors reportedly refused to accept blood donations from Muslims or donors of Turkish origin due to the risk of Hepatitis B. Hopefully Nucleic-Acid Amplification testing (NAT) is standard for all Austrian blood donations. Read more.

Fighting Hepatitis B and Liver Cancer in West Africa
Feb 10 – European Union (EU) funded researchers are identifying and treating patients with Hepatitis B virus in West Africa with the aim of reducing their risk of dying from HBV and liver cancer through project PROLIFCIA. Read more.

China the Hardest Hit by Global Surge in Cancer, Says WHO Report
Feb 10 – China is bearing the brunt of new cancer cases and deaths amid an alarming global rise in the disease, with about 50% of new liver cancer cases recorded in China. Read more.

Hepatitis B and Kidney Transplantation
Feb 10 – Evaluating patients with hepatitis B serologies and HBV DNA viral load prior to kidney transplantation is essential to a successful kidney transplant for those with a current or prior hepatitis B infection. Read more.

CDC: Check Vaccines Before Attending Winter Olympics
Feb. 3 – Before attending the Winter Olympics in Sochi, Russia, U.S. health officials recommend travelers ensure their vaccinations are up to date, including hepatitis B. Read more.

Fish Spa May Spread HIV, Hepatitis B, Expert Warns
Feb. 3 – Fish spas are creating quite a splash in many areas, but health experts warn that the pedicures, where tiny fish nibble away the dead skin, may spread blood diseases such as HIV and hepatitis B. Read more.

British MPs Suggest Law to Ban Visas to Those Suffering From HIV and HBV
Feb 3 – Britain is mulling a draconian law that would ban foreigners with HIV and Hepatitis B from living or visiting the UK, which has caused uproar with civil society and activists urging rejection of the amendment. Read more.

B.C. Funds Hepatitis B Awareness Program for Asian Immigrants
Feb 3 – After years of lobbying, B.C.’s Ministry of Health is spending $400,000 on a hepatitis B education program aimed at Asian immigrants with Mandarin and Korean public information sessions scheduled first, to be followed with Punjabi, Tagalog and English. Read more.

NGMC Recognized for Protecting Newborns From Hepatitis B
Jan 27 – Northeast Georgia Medical Center (NGMC) has been recognized by the Immunization Action Coalition (IAC) and the Georgia Department of Public Health for achieving one of the highest reported rates in the state for its work to protect newborns from hepatitis B virus infection. Read more.

Children’s Patients May be at Risk of Infection After Colonoscopies
Jan 27 – More than 100 patients who had colonoscopies between 2011 and 2013 at Seattle Children’s have been advised to be tested for hepatitis B and C and HIV after the hospital discovered special equipment used in the procedures had not been properly cleaned. Read more.

Cooking Up Cancer?
Jan 27 – Grilling meats is an American tradition, but it’s not the healthiest thing to do. Research suggests that cooking meats over a flame is linked to liver and other cancers due to exposure to polycyclic aromatic hydrocarbons (PAHs). Read more.

Omega-3 Fatty Acids May Have Even More Health Benefits Than Thought
Jan 27 – Recent research shows that omega-3 fatty acids may offer protection against diet-induced nonalcoholic fatty liver disease (NAFLD), which can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma and liver failure. Read more.

Monitoring Inactive Hepatitis B Patients is a Cost-Effective Strategy
Jan 21 – A novel study determined that monitoring inactive chronic hepatitis B carriers is a cost-effective strategy for China. However, results published in Hepatology show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level. Read more.

Patients of Dentist at North Sydney Clinics, Australia, Informed of Possible Exposure to HIV, Hepatitis
Jan 21 – Almost 1000 patients treated by a Sydney dentist over the past decade may have been exposed to HIV and hepatitis B and C because medical equipment was not properly sterilized. Patient advocates say the case raises ''deeply concerning'' questions about patient safety in dental clinics and the quality of medical regulation. Read more.

Cigarettes More Dangerous Than Ever
Jan 21 - Smoking cigarettes can cause even more health problems than previously known, including liver and colon cancer, blindness, diabetes, and erectile dysfunction, said a major US government report on Friday. Read more.

Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program
Jan 13 – The current CDC perinatal hepatitis B prevention program, is a cost-effective use of resources, but a program that reached all pregnant women would provide additional public health benefits, according to results of a recent analysis. Read more.

China Focus: Panic Leads to Drop in Hepatitis B Vaccination Rate
Jan 13 – Panic triggered by alleged vaccine-related deaths in China led to a 30 percent drop in the hepatitis B vaccination rate in December, with experts warning of rising incidence of HBV infection, despite conclusions by health authorities that the vaccine was not responsible for the deaths. Read more.

Nurse exposed 24 Buckeye inmates to hepatitis B and C
Jan 13 – For the second time in 17 months, inmates at the State Prison Complex-Lewis have been exposed to life-threatening disease by a health-care provider as a result of improper injection practices. Read more.

China Denies Hepatitis Vaccine Killed Nine Children
Jan 6 – Vaccines did not cause the deaths of nine children shortly after they were inoculated for hepatitis B as part of the Chinese government program, and no links have been found in eight other cases still being investigated by Chinese health authorities. Read more.

Hepatitis B and C Reduce Survival by More than 20 Years
Jan 6 – People with chronic hepatitis B or C lived about 2 decades less on average than those who did not have these infections, and chronic viral hepatitis was the 15th leading cause of death in the U.S. in 2010, CDC researchers reported in the January 1, 2014 Issue of Clinical Infectious Diseases. Read more.

Nigerian Federal Government Inaugurates Technical Group on Hepatitis Disease Control
Jan 6 – The Nigerian Federal Government has inaugurated a Technical Working Group on Viral Hepatitis Control in Nigeria, as a quick intervention on the increasing burden of viral hepatitis in a country where there is an 11% prevalence of HBV and 2.2% HCV prevalence. Read more.

Surgery Tied to Better Survival Outcomes in Huge Liver Tumors
Jan 6 – Surgical resection of huge hepatocellular carcinomas was linked with better survival outcomes versus transarterial chemoembolization (TACE), researchers found. Read more.



Archived News Stories

*Please Note: Links to archived articles may have expired. If you are unable to access the page via the links below, try searching the HBV Research List Archives at

Archives: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

amazon smile

Connect with Us

facebook twitter youtube linkedin
Hep B Blog
Bookmark and Share
Site design by Ferguson Lynch  FL logo